Immutep (IMMP) announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer, 1L NSCLC. “The receipt of regulatory ...
Immutep Limited announces a poster presentation on the TACTI-004 Phase III trial at the European Lung Cancer Congress 2025. Immutep Limited announced an upcoming poster presentation for its pivotal ...
Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...
TACTI-004 trial evaluates efti with Keytruda and chemotherapy for advanced NSCLC, focusing on progression-free and overall survival. Efti's unique MHC Class 2 agonist mechanism shows strong efficacy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results